A New Contender in AKI Prevention: LSALT Peptide Enters Phase II Momentum

Acute kidney injury (AKI) remains one of the most overlooked complications in modern medicine. Especially after cardiac surgery, the risk is high—and the treatment options? Nearly nonexistent.

Now, Arch Biopartners Inc. is pushing forward with a potential breakthrough.

Phase II Trial Gains Traction Across Canada

Arch has officially begun patient dosing at St. Michael’s Hospital, part of Unity Health Toronto. This marks an important milestone:

• St. Michael’s becomes the third active Canadian site
• Other recruiting centers include:
  • Toronto General Hospital
  • University of Calgary Cumming School of Medicine
• Royal Columbian Hospital is preparing to begin recruitment

The expansion signals one thing: momentum is building.

What the Trial Is Really Testing?

At the center of this study is LSALT peptide, Arch’s lead drug candidate.

The trial design is robust:

• Type: Randomized, double-blind, placebo-controlled
• Scale: 240 patients globally
• Target: Cardiac surgery-associated AKI (CS-AKI)
• Dosage: 10 mg IV, twice daily for five days

The primary goal is simple but critical: Measure how many patients develop AKI within 7 days after surgery. Diagnosis follows Kidney Disease: Improving Global Outcomes (KDIGO) criteria.

Early Signals: Safety Looks Clean

So far, the data is encouraging:

• No serious adverse events linked to LSALT
• No SUSARs reported
• AKI cases are being consistently observed (validating study design)

In clinical trials, no bad news is often good news, especially at this stage.

Why CS-AKI Is So Hard to Solve?

AKI after cardiac surgery isn’t random. It follows a predictable biological chain reaction:

1. Ischemia: Blood flow to kidneys drops
2. Reperfusion: Blood returns
3. Inflammation spike: Damage worsens

This process—called ischemia-reperfusion injury (IRI)—can lead to:

• Kidney failure
• Dialysis dependency
• Even transplant in severe cases

And here’s the problem: There are currently no approved drugs to prevent this.

LSALT’s Mechanism: Targeting Inflammation at the Source

LSALT works differently. It targets the DPEP1 enzyme, which plays a key role in triggering organ inflammation. What makes this interesting:

• DPEP1 is highly expressed in kidneys
• Blocking it may reduce inflammation-driven damage

Preclinical studies (published in Cell and Science Advances) showed:

• Reduced kidney injury from IRI
• Strong biological rationale for human trials

Proof of Concept Already Exists

This isn’t LSALT’s first rodeo. In a prior Phase II study (published in BMJ Open), LSALT was tested for lung inflammation.

Key findings:

• Reduced inflammation biomarkers
• Significant drop in CXCL10 (linked to organ inflammation)
• First-in-human validation of DPEP1 as a target

Translation: The mechanism works in humans.

Expansion Plans: Eyes on the U.S.

Arch isn’t slowing down. They are actively:

• Evaluating 3 U.S. trial sites
• Adding one more Ontario site
• Finalizing budgets and agreements

The goal is clear: Speed up recruitment and increase clinical visibility

Parallel Strategy: The PONTiAK Trial

While LSALT tackles surgery-related AKI, another study is targeting a different cause. Enter the PONTiAK trial. This Phase II study evaluates cilastatin for preventing AKI caused by toxic drugs.

• Recruiting in Calgary and Edmonton
• Target enrollment: 698 patients
• Focus: Drug-induced kidney damage

So far:

• No drug-related adverse events reported
• Recruitment is ongoing

Arch is also planning a U.S. expansion for this program.

The Bigger Picture: A Massive Unmet Need

Let’s put things into perspective:

• Up to 30% of cardiac surgery patients develop AKI
• 14–26% of AKI cases are linked to medications
• Some studies show up to 25% incidence with nephrotoxic drugs

And the long-term risks?

• Chronic kidney disease (CKD)
• Cardiovascular complications
• Increased mortality

Despite this: No approved preventive therapies exist

Final Take: First-in-Class or Just Early Hype?

Arch is positioning LSALT as a first-in-class therapy for inflammation-driven organ injury.

That’s a bold claim—but not unfounded. What works in their favor:

• Strong biological mechanism
• Clean safety profile (so far)
• Early human validation
• Expanding trial footprint

What remains uncertain:

• Will efficacy hold at scale?
• Can it outperform standard care?
• Will regulators buy into the endpoint data?

Bottom Line

If LSALT succeeds, it won’t just be another drug launch. It could redefine how we prevent organ damage in high-risk patients. And in a space with zero approved options, that’s not incremental. That’s disruptive.